Futuximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Futuximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetHER1
Clinical data
Other names992 DS
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6468H10002N1724O2055S46
Molar mass146269.94 g·mol−1

Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2][3]

This drug was developed by Symphogen.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  3. ^ Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.